SPY734.25+0.17%QQQ651.16+0.63%BTC/USD75,635.90−0.44%DIA513.35−0.18%GLD374.92−0.15%TLT81.84−0.11%

Premium Services

Carlsmed Inc

CARLNASDAQ

Trade with Public

Trade with Public

$15.32

-0.77-4.79%

Last update: Nov 5, 5:30 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Carlsmed (CARL) Stock Price Target 2026

The average analyst price target for Carlsmed is $19.20, 23.2% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $17 to $24. The latest change came on Oct 12, 2026, when BTIG raised its price target on Carlsmed from $23 to $24 and kept a Buy rating.

The Average Analyst Price Target for Carlsmed is $19.20.

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$19.20Upside to Avg. PT+23.2%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Carlsmed Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$23→$24
Sep 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$23
Aug 6, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$18→$20
Jul 1, 2026	Needham	David Saxon	Initiate	Buy	$17
May 6, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$23
Apr 15, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$20→$18
Apr 9, 2026	Goldman Sachs	David Roman	PT Cut	Buy	$19→$17
Dec 15, 2025	BTIG	Ryan Zimmerman	Maintained	Buy	$24
Nov 7, 2025	Truist Securities	Richard Newitter	PT Raise	Buy	$18→$20
Nov 7, 2025	BTIG	Ryan Zimmerman	PT Raise	Buy	$21→$24
Aug 18, 2025	Truist Securities	Richard Newitter	Initiate	Buy	$18
Aug 18, 2025	Goldman Sachs	David Roman	Initiate	Buy	$19
Aug 18, 2025	Piper Sandler	Matt O'Brien	Initiate	Overweight	$18

Analyst Ratings News

PRO
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24

BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target

BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17

Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ:CARL) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Carlsmed, Lowers Price Target to $18

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $20 to $18.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Carlsmed, Lowers Price Target to $17

Goldman Sachs analyst David Roman maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $19 to $17.

Benzinga Newsdesk